<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03202134</url>
  </required_header>
  <id_info>
    <org_study_id>2019OSOFADIEPFLAP</org_study_id>
    <nct_id>NCT03202134</nct_id>
  </id_info>
  <brief_title>Impact of Opioid Free Anesthesia on Outcome After DIEPflap Surgery</brief_title>
  <acronym>DIEPflap</acronym>
  <official_title>Impact of Opioid Free Anesthesia on the Complications After DIEPflap Surgery: A Retrospective Observational Cohort Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AZ Sint-Jan AV</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AZ Sint-Jan AV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Deep Inferior Epigastric Perforator free flap (DIEPflap) involves the transfer of&#xD;
      abdominal tissue to the breast using microsurgery. Flap failure is rare today, but is&#xD;
      devastating.&#xD;
&#xD;
      Blood flow in a DIEPflap decreases during the first hours. Many anesthetic factors like low&#xD;
      cardiac output, hypothermia and surgical stress cause vasoconstriction or thrombosis.&#xD;
&#xD;
      A stable anesthesia during these long procedures improves flap perfusion. Postoperative&#xD;
      nausea and vomiting (PONV) is frequent and might have an impact.&#xD;
&#xD;
      Opioid free anesthesia (OFA) reduces PONV. The anti-inflammatory and vasodilator effects of&#xD;
      the drugs dexmedetomidine and lidocaine might improve free flap perfusion.&#xD;
&#xD;
      The primary outcome counted all complications. The secondary outcomes were PONV, pain, opioid&#xD;
      consumption, skin flap temperature and length of hospital stay.&#xD;
&#xD;
      Patients get according to attending anesthesiologist an opioid or opioid free anesthesia&#xD;
      without any randomization but based on availability of competence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators included all patients in the hospital database.belgium who underwent&#xD;
      DIEPflap surgery between Jan 2014 and April 2019. All patients entering the hospital provided&#xD;
      consent to allow retrospective data analysis without patient identification.&#xD;
&#xD;
      Because patient assignment to an operating day was determined without knowing who would&#xD;
      perform the anesthesia on a few exceptions, the choice of opioid free anesthesia (OFA) or&#xD;
      opioid anesthesia (OA) in most cases was random. Patients were classified as receiving OFA&#xD;
      when no opioids were given pre- or intra- operatively until wound closure. Opioids given&#xD;
      after wound closure were counted as post-operative opioids. Patients who received a lower&#xD;
      dose of intra-operative opioids by using additives were still classified as OA.&#xD;
      Post-operative opioid free analgesia was classified as receiving no opioids after wound&#xD;
      closure until discharge from hospital in patients not receiving medium- or long-acting&#xD;
      opioids, pre- or intra-operatively.&#xD;
&#xD;
      The method of reaching OFA remained stable since 2014. Dexmedetomidine was given in a first&#xD;
      loading dose of 0.3 mcg/kg 15 minutes before induction, a second loading dose of 0.1 mcg/kg&#xD;
      at induction followed by an infusion of 0.1 mcg/kg/h for maintenance. Lidocaine is given as a&#xD;
      loading dose of 1 mg/kg at induction followed by 1 mg/kg/h for maintenance. A Ketamine&#xD;
      loading dose of 0.1 mg/kg is given at induction with an extra bolus of 0.7 mg/kg (or max 50&#xD;
      mg) before incision followed by an infusion of 0.1mg/kg/h.&#xD;
&#xD;
      Post-operative analgesia was further improved by continuing very low doses of dexmedetomidine&#xD;
      (0.05 mcg/kg/h), ketamine (0.05 mg/kg/h), and lidocaine (0.5 mg/kg/h) for the first hours&#xD;
      (maximum 5 hours) with the possibility of giving a bolus of 10 mg lidocaine, 1 mg ketamine&#xD;
      and 1 mcg dexmedetomidine every 15 minutes.&#xD;
&#xD;
      OA was induced with sufentanil (0.1 - 0.3 mcg/kg) and continued with extra boli (0.1 - 0.2&#xD;
      mcg/kg) or a continuous infusion of remifentanil (0.20 - 0.35 mcg/kg/h). Since 2014 more and&#xD;
      more additives like clonidine, dexmedetomidine, ketamine and lidocaine were given as a single&#xD;
      additive at the induction to reduce the total dose of intraoperative opioid use. Nevertheless&#xD;
      these patients were still counted as OA.&#xD;
&#xD;
      All patients getting OFA got a strict goal directed fluid therapy with an average amount of&#xD;
      fluids between 600 and 1200 ml. Patients on OA got a more liberal fluid therapy resulting in&#xD;
      total amounts between 3000 and 5000 ml. For each patient the total amount of fluids given&#xD;
      intra operative and the duration of the surgical procedure is calculated.&#xD;
&#xD;
      Following demographic data was retrieved: age, body mass index (BMI), American society of&#xD;
      anesthesiology (ASA) score, incidence of hypertension, smoking or history of recent smoking,&#xD;
      motion sickness or previous PONV. A bilateral DIEPflap is noted as bilat versus unilat and&#xD;
      depending on the use of opioids postoperative an Apfel score is calculated. The number of&#xD;
      anti emetic drugs given before any PONV took place and the number given after PONV is&#xD;
      calculated, the incidence of nausea and the incidence of vomiting is measured. The maximum&#xD;
      visual analog score (VAS) during the first 24 hours and the total equivalent dose of morphine&#xD;
      used in the first 24 hours is measured.&#xD;
&#xD;
      Postoperative flap skin temperature was measured every hour in the first 24 hours and&#xD;
      compared to a reference skin temperature close by.&#xD;
&#xD;
      Perioperative complications during the first post-operative month were graded according to a&#xD;
      score (CLAVIEN), (DINDOO).&#xD;
&#xD;
      DIEPflap failure was defined as the need for a revision procedure that fails in preserving&#xD;
      the flap and requires a new or other flap procedure.&#xD;
&#xD;
      The investigators calculated length of hospital stay (LOS) as the total number of nights in&#xD;
      hospital after surgery.&#xD;
&#xD;
      The investigators retrieved all measured factors potentially related to complications of&#xD;
      grade I to grade V or healthcare utilization outcomes from the database and medical records.&#xD;
      Post-operative opioids were defined as the total dose of opioids used during the first 24&#xD;
      hours post-operatively, calculated as iv morphine equivalents. The following were considered&#xD;
      equivalent to 1 mg iv morphine: 1 mg iv or subcutaneous piritramide, 10 mg iv tramadol, or 2&#xD;
      mg sublingual oxycodone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Actual">November 15, 2019</completion_date>
  <primary_completion_date type="Actual">November 15, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Month</target_duration>
  <primary_outcome>
    <measure>Number of Patients With One or More Complications</measure>
    <time_frame>One month postoperative</time_frame>
    <description>number of minor and major complications (CLAVIEN) (DINDOO)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Post Operative Nausea or Vomiting</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>number of patients having Post operative nausea or vomiting (PONV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Pain: Visual Analog Scale</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>postoperative Pain measured by visual analog scale: 0: no pain. 10 max pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphine Used</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>morphine consumed in mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Temperature</measure>
    <time_frame>24 hours post operative</time_frame>
    <description>temperature difference between free flap skin and central patient skin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>up to two weeks</time_frame>
    <description>length of hospital stay in days</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">204</enrollment>
  <condition>Major and Minor Surgical Complications</condition>
  <arm_group>
    <arm_group_label>opioid free anesthesia (OFA)</arm_group_label>
    <description>The method of reaching OFA: Dexmedetomidine was given in a first loading dose 15 minutes before induction, a second loading dose at induction followed by an infusion for maintenance. Lidocaine is given as a loading dose at induction followed by infusion for maintenance. A Ketamine loading dose is given at induction with an extra bolus before incision followed by an infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>opioid anesthesia (OA)</arm_group_label>
    <description>OA was induced with sufentanil and continued with extra boli or a continuous infusion of remifentanil.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>opioid free anesthesia</intervention_name>
    <description>general anesthesia blocking reflexes without using an opioid</description>
    <arm_group_label>opioid free anesthesia (OFA)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        woman who are admitted for breast reconstruction using the diepflap (free flap)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: DIEPflap unilat or bilat woman between 18 and 60 years old-&#xD;
&#xD;
        Exclusion Criteria: none&#xD;
&#xD;
          -  allergy to any of the drugs used in anesthesia&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>breast reconstructive surgery is included</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Paul Mulier</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZSint Jan AV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azsintjan</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 26, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2017</study_first_posted>
  <results_first_submitted>December 10, 2019</results_first_submitted>
  <results_first_submitted_qc>February 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 23, 2021</results_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AZ Sint-Jan AV</investigator_affiliation>
    <investigator_full_name>Jan Mulier</investigator_full_name>
    <investigator_title>chairman dep anesthesiology &amp; Reanimation</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT03202134/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Opioid Free Anesthesia (OFA)</title>
          <description>The method of reaching OFA: Dexmedetomidine was given in a first loading dose 15 minutes before induction, a second loading dose at induction followed by an infusion for maintenance. Lidocaine is given as a loading dose at induction followed by infusion for maintenance. A Ketamine loading dose is given at induction with an extra bolus before incision followed by an infusion.&#xD;
opioid free anesthesia: general anesthesia blocking reflexes without using an opioid</description>
        </group>
        <group group_id="P2">
          <title>Opioid Anesthesia (OA)</title>
          <description>OA was induced with sufentanil and continued with extra boli or a continuous infusion of remifentanil.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="149"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="149"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Opioid Free Anesthesia (OFA)</title>
          <description>The method of reaching OFA: Dexmedetomidine was given in a first loading dose 15 minutes before induction, a second loading dose at induction followed by an infusion for maintenance. Lidocaine is given as a loading dose at induction followed by infusion for maintenance. A Ketamine loading dose is given at induction with an extra bolus before incision followed by an infusion.&#xD;
opioid free anesthesia: general anesthesia blocking reflexes without using an opioid</description>
        </group>
        <group group_id="B2">
          <title>Opioid Anesthesia (OA)</title>
          <description>OA was induced with sufentanil and continued with extra boli or a continuous infusion of remifentanil.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="149"/>
            <count group_id="B3" value="204"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="55"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.9" spread="2.8"/>
                    <measurement group_id="B2" value="50.3" spread="1.7"/>
                    <measurement group_id="B3" value="51.6" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Sex:Female</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="55"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>history of nausea after anesthesia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="55"/>
                    <count group_id="B2" value="149"/>
                    <count group_id="B3" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With One or More Complications</title>
        <description>number of minor and major complications (CLAVIEN) (DINDOO)</description>
        <time_frame>One month postoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Opioid Free Anesthesia (OFA)</title>
            <description>The method of reaching OFA: Dexmedetomidine was given in a first loading dose 15 minutes before induction, a second loading dose at induction followed by an infusion for maintenance. Lidocaine is given as a loading dose at induction followed by infusion for maintenance. A Ketamine loading dose is given at induction with an extra bolus before incision followed by an infusion.&#xD;
opioid free anesthesia: general anesthesia blocking reflexes without using an opioid</description>
          </group>
          <group group_id="O2">
            <title>Opioid Anesthesia (OA)</title>
            <description>OA was induced with sufentanil and continued with extra boli or a continuous infusion of remifentanil.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With One or More Complications</title>
          <description>number of minor and major complications (CLAVIEN) (DINDOO)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Post Operative Nausea or Vomiting</title>
        <description>number of patients having Post operative nausea or vomiting (PONV)</description>
        <time_frame>24 hours postoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Opioid Free Anesthesia (OFA)</title>
            <description>The method of reaching opioid free anesthesia (OFA): Dexmedetomidine was given in a first loading dose 15 minutes before induction, a second loading dose at induction followed by an infusion for maintenance. Lidocaine is given as a loading dose at induction followed by infusion for maintenance. A Ketamine loading dose is given at induction with an extra bolus before incision followed by an infusion.&#xD;
opioid free anesthesia: general anesthesia blocking reflexes without using an opioid</description>
          </group>
          <group group_id="O2">
            <title>Opioid Anesthesia (OA)</title>
            <description>opioid anesthesia (OA) was induced with sufentanil and continued with extra boli or a continuous infusion of remifentanil.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Post Operative Nausea or Vomiting</title>
          <description>number of patients having Post operative nausea or vomiting (PONV)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Pain: Visual Analog Scale</title>
        <description>postoperative Pain measured by visual analog scale: 0: no pain. 10 max pain</description>
        <time_frame>24 hours postoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Opioid Free Anesthesia (OFA)</title>
            <description>The method of reaching OFA: Dexmedetomidine was given in a first loading dose 15 minutes before induction, a second loading dose at induction followed by an infusion for maintenance. Lidocaine is given as a loading dose at induction followed by infusion for maintenance. A Ketamine loading dose is given at induction with an extra bolus before incision followed by an infusion.&#xD;
opioid free anesthesia: general anesthesia blocking reflexes without using an opioid</description>
          </group>
          <group group_id="O2">
            <title>Opioid Anesthesia (OA)</title>
            <description>OA was induced with sufentanil and continued with extra boli or a continuous infusion of remifentanil.</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Pain: Visual Analog Scale</title>
          <description>postoperative Pain measured by visual analog scale: 0: no pain. 10 max pain</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="0.65"/>
                    <measurement group_id="O2" value="4.94" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morphine Used</title>
        <description>morphine consumed in mg</description>
        <time_frame>24 hours postoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Opioid Free Anesthesia (OFA)</title>
            <description>The method of reaching OFA: Dexmedetomidine was given in a first loading dose 15 minutes before induction, a second loading dose at induction followed by an infusion for maintenance. Lidocaine is given as a loading dose at induction followed by infusion for maintenance. A Ketamine loading dose is given at induction with an extra bolus before incision followed by an infusion.&#xD;
opioid free anesthesia: general anesthesia blocking reflexes without using an opioid</description>
          </group>
          <group group_id="O2">
            <title>Opioid Anesthesia (OA)</title>
            <description>OA was induced with sufentanil and continued with extra boli or a continuous infusion of remifentanil.</description>
          </group>
        </group_list>
        <measure>
          <title>Morphine Used</title>
          <description>morphine consumed in mg</description>
          <units>milligram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="0.84"/>
                    <measurement group_id="O2" value="4.94" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Skin Temperature</title>
        <description>temperature difference between free flap skin and central patient skin</description>
        <time_frame>24 hours post operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Opioid Free Anesthesia (OFA)</title>
            <description>The method of reaching OFA: Dexmedetomidine was given in a first loading dose 15 minutes before induction, a second loading dose at induction followed by an infusion for maintenance. Lidocaine is given as a loading dose at induction followed by infusion for maintenance. A Ketamine loading dose is given at induction with an extra bolus before incision followed by an infusion.&#xD;
opioid free anesthesia: general anesthesia blocking reflexes without using an opioid</description>
          </group>
          <group group_id="O2">
            <title>Opioid Anesthesia (OA)</title>
            <description>OA was induced with sufentanil and continued with extra boli or a continuous infusion of remifentanil.</description>
          </group>
        </group_list>
        <measure>
          <title>Skin Temperature</title>
          <description>temperature difference between free flap skin and central patient skin</description>
          <units>degrees Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" spread="0.25"/>
                    <measurement group_id="O2" value="1.41" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.048</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospital Stay</title>
        <description>length of hospital stay in days</description>
        <time_frame>up to two weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Opioid Free Anesthesia (OFA)</title>
            <description>The method of reaching OFA: Dexmedetomidine was given in a first loading dose 15 minutes before induction, a second loading dose at induction followed by an infusion for maintenance. Lidocaine is given as a loading dose at induction followed by infusion for maintenance. A Ketamine loading dose is given at induction with an extra bolus before incision followed by an infusion.&#xD;
opioid free anesthesia: general anesthesia blocking reflexes without using an opioid</description>
          </group>
          <group group_id="O2">
            <title>Opioid Anesthesia (OA)</title>
            <description>OA was induced with sufentanil and continued with extra boli or a continuous infusion of remifentanil.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospital Stay</title>
          <description>length of hospital stay in days</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.82" spread="0.26"/>
                    <measurement group_id="O2" value="7.52" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <desc>using the definition of clinical trials for death and serious adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Opioid Free Anesthesia (OFA)</title>
          <description>The method of reaching OFA: Dexmedetomidine was given in a first loading dose 15 minutes before induction, a second loading dose at induction followed by an infusion for maintenance. Lidocaine is given as a loading dose at induction followed by infusion for maintenance. A Ketamine loading dose is given at induction with an extra bolus before incision followed by an infusion.&#xD;
opioid free anesthesia: general anesthesia blocking reflexes without using an opioid</description>
        </group>
        <group group_id="E2">
          <title>Opioid Anesthesia (OA)</title>
          <description>OA was induced with sufentanil and continued with extra boli or a continuous infusion of remifentanil.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Revision surgery</sub_title>
                <description>Revision surgery for problem of vascularization, hematoma or other surgical reason.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Post operative nausea and vomiting</sub_title>
                <description>PONV: Minor complications graded by CLAVIEN and DINDOO as score 1</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E2" events="67" subjects_affected="67" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jan Mulier</name_or_title>
      <organization>AZSintJanAV</organization>
      <phone>003250452490</phone>
      <email>jan.mulier@azsintjan.be</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

